Medicenna in the spotlight (part II)

Evaluating recent developments in cytokine-based therapies

Following up on our part I introductory post about Medicenna Therapeutics (MDNA) and recent update on first patient dosage in their clinical trials, MDNA stock has been stuck in the mud, trading under $2.50. The next key catalyst will be biomarker data for MDNA11 for solid tumors by year end 2021. We expect a run-up into that data.

Yesterday, Merck & Syn…